Isatuximab

Safety & efficacy of isatuximab, pomalidomide and dexamethasone in frail patients with R/R myeloma 1:50
Safety & efficacy of isatuximab, pomalidomide and dexamethasone in frail patients with R/R myeloma
Karthik Ramasamy • 22 Nov 2022
Updates from ICARIA-MM: longer-term efficacy data on the combination of Isa-Pd in R/R myeloma 2:12
Updates from ICARIA-MM: longer-term efficacy data on the combination of Isa-Pd in R/R myeloma
Paul Richardson • 11 Dec 2022
SKylaRk: Phase II study of Isa-KRD in newly diagnosed, transplant-eligible multiple myeloma 2:17
SKylaRk: Phase II study of Isa-KRD in newly diagnosed, transplant-eligible multiple myeloma
Noopur Raje • 11 Dec 2022
ITHACA trial results: combination of isatuximab, lenalidomide & dexamethasone for high-risk SMM 0:58
ITHACA trial results: combination of isatuximab, lenalidomide & dexamethasone for high-risk SMM
Irene Ghobrial • 11 Dec 2022
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma 1:33
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma
Thomas Martin • 30 Sep 2022
The standard of care in multiple myeloma & emerging treatment options 1:38
The standard of care in multiple myeloma & emerging treatment options
Denis O’Keeffe • 8 Nov 2022
Options for the treatment of patients with R/R multiple myeloma 5:02
Options for the treatment of patients with R/R multiple myeloma
Claudio Cerchione • 28 Sep 2022
Current status & updates in the management of AL amyloidosis 5:14
Current status & updates in the management of AL amyloidosis
Meral Beksac • 8 Oct 2022
Choosing between isatuximab & daratumumab in multiple myeloma 4:01
Choosing between isatuximab & daratumumab in multiple myeloma
Rahul Banerjee • 26 Aug 2022
Feasibility and impact of digital health interventions on the QoL of patients with R/R myeloma 1:54
Feasibility and impact of digital health interventions on the QoL of patients with R/R myeloma
Rahul Banerjee • 26 Aug 2022
Real-world safety & efficacy of isatuximab-pomalidomide-dexamethasone in R/R multiple myeloma 1:45
Real-world safety & efficacy of isatuximab-pomalidomide-dexamethasone in R/R multiple myeloma
Karthik Ramasamy • 30 Aug 2022
An update on the RADAR trial: RCyBorD as induction therapy in newly diagnosed multiple myeloma 1:46
An update on the RADAR trial: RCyBorD as induction therapy in newly diagnosed multiple myeloma
Karthik Ramasamy • 30 Aug 2022
Current & possible uses of isatuximab in the treatment of myeloma and smoldering myeloma 1:49
Current & possible uses of isatuximab in the treatment of myeloma and smoldering myeloma
Claudio Cerchione • 27 Aug 2022
Elotuzumab & the role of monoclonal antibodies in the treatment of smoldering myeloma 4:00
Elotuzumab & the role of monoclonal antibodies in the treatment of smoldering myeloma
Claudio Cerchione • 27 Aug 2022
Daratumumab vs isatuximab in the treatment of multiple myeloma 1:37
Daratumumab vs isatuximab in the treatment of multiple myeloma
Saad Usmani • 25 Sep 2022
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma 2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals